Managing IP’s Asia-Pacific Special Focus 2022 launched

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Managing IP’s Asia-Pacific Special Focus 2022 launched

MIP Asia-Pacific Editorial Image.jpg

Managing IP has partnered with IP leaders from across the Asia-Pacific region to analyse recent court cases and analyse incoming regulations in India, Korea, and Japan

Click here to read the full Asia-Pacific Special Focus 2022.

First, our writers from Anand and Anand explore the significance of a recent ruling concerning trademark protection of film titles and assess the tests used to establish the copyrightability of characters.

In the case Sholay Media Entertainment & Anr. v Yogesh Patel & Ors., the Delhi High Court held that “certain films cross the boundaries of just being ordinary words and the title of the film ‘SHOLAY’ is one of them”. In other words, movie titles are entitled to trademark protection, providing they have achieved a secondary meaning.

Next the authors from FirstLaw P.C. analyse the impact of a ruling from the Supreme Court of Korea on the inventiveness standards for certain inventions, which is encouraging for pharmaceutical patentees.

In 2021, the Court departed from precedent in holding that, to determine the inventiveness of a selection invention, the difficulty to conceive the selection invention should first be examined. If difficulty cannot be shown, the inventiveness of the selection invention may then be assessed based on the existence of a remarkable effect of the selection invention.

In March 2022, the Court went further and upheld the inventiveness of a specific crystalline form invention without requiring corroboration of the presence of a remarkable effect of the crystalline form invention. The approach adopted by the Supreme Court is a promising sign for patentees in Korea, especially those in the pharmaceutical industry.

Finally, our contributor from Shiga International Patent Office (JPO) explains why the Japan Patent Office has introduced restrictions on multi-multi claims, and offers advice to domestic and overseas patent applicants.

The JPO intends to enhance global harmonisation and reduce the burden of examinations and monitoring by third parties. For both overseas and Japanese applicants, it is important to be aware of the regulations and take measures to avoid unnecessary costs and obtain a patent efficiently.

Click here to read the full Asia-Pacific Special Focus 2022.


more from across site and SHARED ros bottom lb

More from across our site

Counsel explain how the USPTO’s decision to discretionarily deny institution of a PTAB case affects their advice to clients
The Life Sciences Awards announces the winners for the 6th annual awards
The UPC’s plans to roll out its new Case Management System and a setback for TikTok in India were also among the top talking points
Trademark specialist Jonathan Thomas says he’s excited to introduce his clients to other areas of Greenberg Traurig’s practice
Counsel at firms responsible for managing the highest number of registered trademarks explain the secrets behind staying organised and keeping the work flowing in
Attorneys explain what stakeholders should know about Patent Term Adjustments in Brazil, more than three years after a landmark Brazilian Supreme Court ruling
New categories have been added to reflect a changing legal and social landscape
Three sources explain why a notification by Nanjing’s IP centre in China banning AI use in patent drafting is too broad and could be difficult to enforce
Sheppard Mullin’s latest hires explain why the firm's industry expertise impressed them
Elizabeth Godfrey explains why she doesn’t believe in a ‘salesperson’ approach to BD, and reveals how AI is playing an important role at Davies Collison Cave
Gift this article